Lab
Natural State Genomics LLC
Natural State Genomics LLC was paid $4.34M by Medicaid between May 2020 and Feb 2024, across 38 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 88% of everything it billed.
33Billing provider infoNATURAL STATE GENOMICS LLC
LITTLE ROCK, AR 72212
LITTLE ROCK, AR 72212
33aNPI1861032633assigned 01/09/2020
33bProvider typeClinical Medical Laboratory
28Total paid$4.34M
24GClaims279,665
24DCodes billed38
24AFirst – last monthMay 2020 – Feb 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Arkansas
Rank by total paid#1 of 24
Median peer was paid$53K
This provider vs. median81×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 34,120 | $874K | |
| 2021 | 134,542 | $1.98M | |
| 2022 | 105,242 | $1.44M | |
| 2023 | 4,943 | $37K | |
| 2024incomplete | 818 | $9K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 88% | 135,611 | 52,841 | $3.82M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 11% | 17,948 | 8,610 | $477K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 267 | 146 | $7K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,104 | 944 | $6K |
| 87481 | <1% | 1,040 | 929 | $5K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 82 | 43 | $5K |
| 87640 | <1% | 1,042 | 948 | $5K | |
| 87653 | <1% | 992 | 900 | $4K | |
| 87500 | <1% | 816 | 756 | $4K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 114,600 | 44,366 | $3K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 210 | 198 | $3K |
| 87109 | <1% | 586 | 543 | $1K |
26 more codes
| 87631 | <1% | 28 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 175 | $746.09 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 297 | $701.68 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 256 | $692.72 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 111 | $636.54 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 176 | $543.67 |
| 87641 | <1% | 297 | $524.86 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 272 | $478.86 |
| 87181 | <1% | 297 | $387.95 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 18 | $359.25 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,412 | $349.33 |
| 87634 | <1% | 17 | $173.32 | |
| 87581 | <1% | 99 | $150.36 | |
| 87541 | <1% | 99 | $150.36 | |
| 87486 | <1% | 104 | $137.87 | |
| 87498 | <1% | 17 | $101.34 | |
| 87106 | <1% | 61 | $58.50 | |
| 81439 | 0% | 64 | $0.00 | |
| 81408 | 0% | 64 | $0.00 | |
| 81404 | 0% | 64 | $0.00 | |
| 81405 | 0% | 64 | $0.00 | |
| 81406 | 0% | 64 | $0.00 | |
| 81403 | 0% | 64 | $0.00 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 102 | $0.00 |
| 81407 | 0% | 64 | $0.00 | |
| 87496 | 0% | 81 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHONEYCUTT, CASEY (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Natural State Laboratories, LLC | Little Rock, AR | $513K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.